Methodology and results of real-world cost-effectiveness of carfilzomib in combination with lenalidomide and dexamethasone in relapsed multiple myeloma using registry data

OBJECTIVE: To predict the real-world (RW) cost-effectiveness of carfilzomib in combination with lenalidomide and dexamethasone (KRd) versus lenalidomide and dexamethasone (Rd) in relapsed multiple myeloma (MM) patients after one to three prior therapies. METHODS: A partitioned survival model that in...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Eur J Health Econ
Main Authors: Campioni, M., Agirrezabal, I., Hajek, R., Minarik, J., Pour, L., Spicka, I., Gonzalez-McQuire, S., Jandova, P., Maisnar, V.
Formato: Artigo
Idioma:Inglês
Publicado em: Springer Berlin Heidelberg 2019
Assuntos:
Original Paper
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC7072050/
https://ncbi.nlm.nih.gov/pubmed/31673898
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s10198-019-01122-6
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados